

Case IPR2017-00904

Declaration of Dorraya El-Ashry, Ph.D. Under 37 C.F.R. § 1.68 in Support of
Petition for *Inter Partes* Review of U.S. Patent No. 6,774,122

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

INNOPHARMA LICENSING, LLC,
Petitioner

v.

ASTRAZENECA AB,
Patent Owner

Case IPR2017-00904
Patent No. 6,774,122

DECLARATION OF DORRAYA EL-ASHRY, Ph.D., UNDER 37 C.F.R.
§ 1.68 IN SUPPORT OF PETITION FOR *INTER PARTES* REVIEW OF U.S.
PATENT NO. 6,774,122

Mail Stop: Patent Board
Patent Trial and Appeal Board
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

TABLE OF CONTENTS

I. INTRODUCTION..... 1

II. BACKGROUND AND QUALIFICATIONS..... 2

III. MATERIALS CONSIDERED FOR THIS DECLARATION 6

IV. SUMMARY OF OPINIONS..... 6

V. LEVEL OF ORDINARY SKILL IN THE PERTINENT ART.....11

VI. OVERVIEW OF TYPES OF BREAST CANCER AND THE AVAILABLE
THERAPIES AS OF 200012

 A. Hormone-Dependent Breast Cancer12

 (1) SERMs.....13

 (2) AIs.....14

 (3) ERDs.....15

 B. Hormone-Independent Breast Cancer15

VII. OVERVIEW OF THE MCLESKEY REFERENCE.....17

 A. Summary of the Testing Conducted in the McLeskey Reference.....17

 B. Results Reported in the McLeskey Reference19

 C. Conclusions That A Skilled Researcher Would Draw From the
 McLeskey Reference22

VIII. RESPONSE TO THE MCLESKEY DECLARATION23

 A. Fulvestrant Was Not a Treatment Failure23

 B. A Skilled Researcher Would Not Have Concluded That Preformulated
 Fulvestrant Could Only Be Administered to Animals.....25

 C. A Skilled Researcher Would Have Considered the McLeskey Reference

Relevant and Helpful.....	27
IX. CONCLUSION	29

I, Dorraya El-Ashry, Ph.D. hereby declare as follows:

I. INTRODUCTION

1. I have been retained as an expert witness on behalf of InnoPharma Licensing, LLC (“InnoPharma”) for the above-captioned Petition for *Inter Partes* Review (“IPR”) of U.S. Patent No. 6,774,122 (“the ‘122 patent”). I am being compensated for my time in connection with this IPR at my standard consulting rate of \$500 per hour. My compensation is in no way dependent on the outcome of this matter.

2. I have been asked to provide my opinions regarding the article *Tamoxifen-resistant Fibroblast Growth Factor-transfected MCF-7 Cells Are Cross-Resistant in Vivo to the Antiestrogen ICI 182,780 and Two Aromatase Inhibitors*, 4 Clinical Cancer Research 697-711 (1998) (“the McLeskey Reference”). I am an author on the McLeskey Reference, and was the principal estrogen receptor expert on the project. The remaining authors of the McLeskey reference—including Drs. McLeskey and Kern—were growth factor experts, not estrogen receptor experts.

3. I have also been asked to respond to certain opinions set forth in the Declaration of Sandra McLeskey (“the McLeskey Declaration”), which I understand that AstraZeneca AB (“AstraZeneca”) attached as Exhibit 2043 to its

Patent Owner Response in IPR2016-01316, -01324, -01325, and -01326.

4. In preparing this Declaration, I have reviewed the '122 patent, the McLeskey Reference, the McLeskey Declaration, and the article titled *Pharmacokinetics, Pharmacological and Anti-tumor Effects of the Specific Anti-Oestrogen ICI 182780 in Women with Advanced Breast Cancer*, BRITISH J. OF CANCER, 74, p. 300-308 (1996) (“the Howell Reference”).

5. In forming the opinions expressed in this Declaration, I relied upon my education and experience in the relevant field of the art, and have considered the viewpoint of a person having ordinary skill in the relevant art as of 2000.

II. BACKGROUND AND QUALIFICATIONS

6. I received my B.A. in Molecular Biology in 1984 from Vanderbilt University, and my Ph.D. in Experimental Pathology in 1989 from the University of Colorado Health Sciences Center. My dissertation focused on the cellular and molecular properties of progesterone receptors in breast cancer.

7. After completing my Ph.D., I began a Post-Doctoral Fellowship at the Georgetown Lombardi Cancer Center in 1994 in Washington, D.C. My research area was estrogen regulation of TGF- α in breast cancer. While at the Lombardi Cancer Center, I helped draft the McLeskey Reference along with my co-authors, including Dr. McLeskey and Dr. Kern.

8. I was promoted to Research Assistant Professor at the Lombardi

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.